Shanghai Labway Clinical Laboratory Co., Ltd.
SZSE:301060.SZ
12.86 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,674.369 | 4,199.305 | 1,778.333 | 1,238.19 | 1,153.496 | 1,052.73 | 923.237 | 804.647 | 608.47 | 541.04 | 462.695 |
| Cost of Revenue
| 1,345.054 | 2,408.886 | 1,098.441 | 838.355 | 805.034 | 727.848 | 644.466 | 534.717 | 394.955 | 373.545 | 289.956 |
| Gross Profit
| 329.314 | 1,790.419 | 679.892 | 399.835 | 348.462 | 324.882 | 278.771 | 269.93 | 213.516 | 167.495 | 172.738 |
| Gross Profit Ratio
| 0.197 | 0.426 | 0.382 | 0.323 | 0.302 | 0.309 | 0.302 | 0.335 | 0.351 | 0.31 | 0.373 |
| Reseach & Development Expenses
| 48.863 | 109.402 | 39.442 | 21.802 | 18.804 | 16.885 | 13.836 | 0 | 0 | 2.988 | 3.141 |
| General & Administrative Expenses
| 59.181 | 90.515 | 63.204 | -58.994 | -306.799 | -336.828 | -117.804 | 113.057 | 62.498 | 12.176 | 11.81 |
| Selling & Marketing Expenses
| 98.688 | 184.121 | 125.483 | 79.426 | 86.477 | 77.963 | 136.892 | 62.908 | 31.275 | 22.945 | 19.94 |
| SG&A
| 157.868 | 274.636 | 188.686 | 20.432 | -220.321 | -258.865 | 19.088 | 175.965 | 93.773 | 35.121 | 31.75 |
| Other Expenses
| 0 | 260.555 | 121.224 | 170.472 | 412.753 | 15.728 | 5.708 | 0 | 0 | 9.719 | 1.259 |
| Operating Expenses
| 479.969 | 644.593 | 349.352 | 212.706 | 211.235 | 209.267 | 262.845 | 182.613 | 103.536 | 67.745 | 58.801 |
| Operating Income
| -135.824 | 949.276 | 318.947 | 178.466 | 130.555 | 106.678 | 7.139 | 90.51 | 116.573 | 87.87 | 110.876 |
| Operating Income Ratio
| -0.081 | 0.226 | 0.179 | 0.144 | 0.113 | 0.101 | 0.008 | 0.112 | 0.192 | 0.162 | 0.24 |
| Total Other Income Expenses Net
| -17.42 | -44.832 | -0.916 | -16.158 | -4.245 | -1.028 | -1.575 | -3.193 | -6.594 | -10.469 | 0.096 |
| Income Before Tax
| -153.243 | 904.443 | 318.031 | 162.308 | 126.311 | 105.651 | 5.564 | 87.317 | 109.979 | 89.282 | 110.972 |
| Income Before Tax Ratio
| -0.092 | 0.215 | 0.179 | 0.131 | 0.11 | 0.1 | 0.006 | 0.109 | 0.181 | 0.165 | 0.24 |
| Income Tax Expense
| 8.466 | 165.388 | 56.414 | 27.828 | 31.699 | 31.716 | 25.758 | 27.109 | 27.669 | 18.941 | 26.63 |
| Net Income
| -141.591 | 617.323 | 203.84 | 110.376 | 92.242 | 73.386 | 6.418 | 58.764 | 82.311 | 70.34 | 84.342 |
| Net Income Ratio
| -0.085 | 0.147 | 0.115 | 0.089 | 0.08 | 0.07 | 0.007 | 0.073 | 0.135 | 0.13 | 0.182 |
| EPS
| -0.35 | 1.54 | 0.51 | 0.28 | 0.23 | 0.21 | 0.018 | 0.62 | 0.92 | 0.18 | 0.21 |
| EPS Diluted
| -0.35 | 1.54 | 0.51 | 0.28 | 0.23 | 0.21 | 0.018 | 0.62 | 0.92 | 0.18 | 0.21 |
| EBITDA
| -59.009 | 1,014.903 | 392.496 | 215.632 | 175.203 | 148.507 | 37.404 | 109.875 | 128.632 | 108.205 | 117.481 |
| EBITDA Ratio
| -0.035 | 0.281 | 0.223 | 0.2 | 0.173 | 0.215 | 0.061 | 0.137 | 0.211 | 0.207 | 0.258 |